News

Martin Kulldorff, PhD, answers whether an age based coronavirus strategy would worsen the pandemic's impact on workers and minority racial groups.

Investigators report comparable SARS-CoV-2 neutralizing antibody counts across age groups, as well as favorable safety outcomes for the two-dose vaccine.

Soon after visiting 38 hospitals in Michigan, over half of patients hospitalized with suspected COVID-19 received antibiotics.

The US Centers for Disease Control and Prevention has updated COVID-19 guidance, sharing advice on safe travel

ARCC made the announcement yesterday that the WHO African Region is free of the virus.

ViiV Healthcare’s dolutegravir/lamivudine (Dovato) may be potential treatment option for this patient population

Hospitals considering interventions to reduce Clostridioides difficile infections may find that less is more, according to a new study that found daily cleaning with sporicidal products to be the most cost-effective single infection control strategy.

John Johnson, lead for Ebola vaccination with MSF France, describes the "ring strategy" used in controlling several infectious disease threats.

Martin Kulldorff, PhD, takes a total social health perspective on the global use of mass quarantines as a primary COVID-19 control strategy.

Brad Spellberg, MD, discusses how the subspecialty lost "ownership" of its opportunities for pattented prescribing and referral years ago.

Company says investigational therapeutic could afford at least 6 months of protection from the virus.

Incomplete data tells only half the story, and this story is devastating.

This could be an important feature in potential vaccine development.

Regeneron will distribute a prospective therapy in the US and Roche will be responsible for it internationally.

Investigators observed a second set of virus in a previously infected 33-year-old man, nearly 5 months after his first positive COVID-19 case.

An infectious disease chief medical officer discusses the cracks in US healthcare exposed by the pandemic.

Obesity was a risk factor for intubation and death from COVID-19 for adults under the age of 65.

The newest authorization comes following a week of clinical, legislative, and public health debate surrounding the realistic benefit of the survivor-extracted therapy.

Martin Kulldorff, PhD, explains the standard Sweden uses to collect data on the country's seemingly high COVID-19 mortality.

The IDSA recommends against its use in the hospital setting.

A refresher on the week's developments in the infectious disease drug & medical device FDA approval pipeline.

FDA is working with local partners to continue the outbreak investigation.

The latest Ebola outbreak in western Democratic Republic of Congo has led to at least 100 cases as of Friday, according to WHO.

Martin Kulldorff, PhD, explains how an age-based focus for COVID-19 mitigation might better protect both older people and younger people with comorbidities.

School administrators, nurses and teachers are trying to develop plans to bring students back for critical in-school learning while keeping staff and immune-suppressed students safe.

The vaccine candidate, BNT162b2, was well-tolerated and phase 3 enrollment is more than one-third complete.

HIV-positive to HIV-positive kidney and liver transplantation showed no evidence of HIV superinfection, a new study in The Lancet HIV found.

Rodney E. Rohde, a clinical laboratory specialist at Texas State University, goes into the competing priorities of college and K-12 school reopening.

Scientists are willing to speak out and have collegial debates – but medical institutions and media have to catch up: fringe voices are often the only ones platformed to discuss important scientific nuances or debates.

In unexposed blood samples, investigators discovered memory helper T cells that recognize cold coronaviruses also recognized SARS-CoV-2, and may help people fight off the virus.